Medulloblastoma(MB) is the most common solid tumor in children and, according to the World Health Organization (WHO), is classified as a central nervous system tumor grade IV. Currently, treatment of this type of cancer consists of surgery, chemotherapy and, depending on the patient's age, radiotherapy. Although survival is high (over 50%) treatment used may cause medium and long term adverse effects. Therefore, studies to identify new therapeutic targets are essential to improve treatment for younger patients (of less than three years old) and to reduce the adverse effects caused by the treatment of this disease. The Polo-like kinases(PLKs) comprise a family of five members of serine / threonine kinases: PLK1, PLK2, PLK3, PLK4 and PLK5, which play key roles in cell cycle control. Several studies have shown that the PLK1 gene is down regulated in different tumors types and is also correlated with prognosis and malignancy of some cancers. There are no reports in the literature on changes in the expression of PLK2, PLK4 and PLK5, however PLK3 has been reported down regulated in some cancer types. In this study we will analyze PLK family genes expression in MB cell lines and samples, and concurrently we will evaluate the effects of PLK1 inhibition with BI 2536, BI 6727, GSK461364 and GW843682X in MB cell lines. It will also be assessed and correlated with expression of miRNAs 100, 126 and 593 * 219-5p, related to the family genes PLK.
News published in Agência FAPESP Newsletter about the scholarship: